Firefly Neuroscience, Inc. AIFF

Firefly Neuroscience and NeuroSigma announced a strategic partnership to bring NeuroSigma's second-generation Monarch eTNS System to Firefly's nationwide Evoke clinician network, pairing FDA-cleared non-drug ADHD treatment with Firefly's AI-powered qEEG/ERP platform and ADHD biomarker research. Firefly will introduce Monarch to psychiatry, neurology and behavioral health practices using Evoke, with NeuroSigma providing clinical training, prescribing support and product fulfillment through its specialty pharmacy partner. Monarch, indicated for children aged 7-12 not on ADHD meds, is shipping after a July 2026 launch; the collaboration aims to improve objective brain-function assessment, offer at-home treatment options, and broaden access amid ADHD prevalence and demand for non-stimulant therapies. Strategic partnership expands access to FDA-cleared non-drug ADHD treatment via Firefly's Evoke network, combining objective brain assessment with at-home Monarch therapy and expanding payer- and biomarker-informed care, potentially boosting adoption and revenue.

Firefly Neuroscience’s Evoke platform has been selected to integrate objective brain-function insights into Radial’s AI-native operating system for brain medicine. Evoke platform selection for Radial’s AI system signals major partnership expanding AIFF adoption in brain medicine.

Firefly Neuroscience reports 291% increase in TMS center customer brain scan volumes. 291% volume growth signals strong customer adoption and revenue potential.

Firefly Neuroscience (AIFF) and Next Health launched a precision cognitive health initiative backed by FDA advisory committee recommendation for broader access to neuroprotective peptides. Initiative launch with FDA peptide access backing signals major strategic growth in cognitive health for AIFF.

Cognito Therapeutics presented data at AAIC 2025 showing that its investigational device, Spectris™, significantly slows cognitive and functional decline in Alzheimer’s patients. The OVERTURE trial results indicated structural neuroprotection, preserving white matter and myelin integrity. Collaboration with Firefly Neuroscience aims to identify EEG biomarkers correlating with Spectris' clinical response. Participants experienced substantial 'time saved' in various cognitive and functional measures, with high adherence rates to the treatment. Spectris is currently under evaluation in a pivotal clinical trial and has not yet received regulatory approval. The collaboration with Firefly Neuroscience and the promising trial results could significantly enhance Firefly's market position and investor sentiment.

Firefly Neuroscience's AI-Driven Evoke System has discovered a novel electrophysiological biomarker for PTSD. Evoke system biomarker discovery marks major advance in core AI technology with strong potential to shift company trajectory.

Firefly Neuroscience accelerates brain scan volume momentum and achieves history by constructing the world’s first known depository of over 200,000 standardized EEG/ERP scans. Establishing the world’s first 200,000+ standardized EEG/ERP depository provides Firefly with unparalleled data assets, redefining its leadership in neuroscience AI and long-term market prospects.

Firefly Neuroscience, Inc. (AIFF) confirms public-private partnership with the Department of War. Public-private partnership with Department of War fundamentally redefines Firefly Neuroscience's competitive position and long-term prospects.

Firefly Neuroscience, Inc. (AIFF) announces discovery of new brain wave biomarkers enabling differential diagnosis of ADHD. Discovery of ADHD-specific brain wave biomarkers advances core neurodiagnostic technology, likely enhancing competitive edge and investor interest.

Firefly Neuroscience progresses toward developing and commercially launching its foundation model of the human brain, powered by NVIDIA GPU acceleration. Progress on a NVIDIA-accelerated brain foundation model represents a major strategic advancement in AI-driven neuroscience.

Firefly Neuroscience, Inc. (AIFF) reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational advancements. The company continues to focus on its innovative neuroscience solutions, aiming to enhance its market position. Management expressed optimism about future developments and ongoing projects that could drive further growth. Revenue growth and operational advancements indicate a moderately noticeable influence on financial performance and market positioning.

Firefly Neuroscience, Inc. has partnered with HealingMaps to provide cognitive electrophysiology analytics to over 2,500 clinics across North America that offer ketamine, psilocybin, and TMS treatments. This collaboration aims to enhance the understanding and effectiveness of these therapies through advanced analytics. The partnership significantly expands Firefly's reach and capabilities in the growing mental health treatment market.

Firefly Neuroscience, Inc. has successfully integrated NVIDIA L40S GPU acceleration into its next-generation CLEAR platform, enhancing its capabilities in neuroscience applications. This deployment is expected to significantly improve processing power and efficiency, positioning Firefly at the forefront of innovation in the field. The integration of advanced GPU technology is likely to enhance product performance and competitive positioning significantly.

Firefly Neuroscience, Inc. (AIFF) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Firefly Neuroscience, Inc. has partnered with Heidelberg University Hospital to study the neurophysiological effects of 15q13.3 copy number variants using its FDA-cleared BNA™ platform. The study will analyze EEG data from 30 subjects to identify biomarkers and neurocognitive profiles linked to these genetic variants, aiming to enhance diagnostic and therapeutic strategies for neurodevelopmental disorders. Firefly will provide EEG systems, training, and analytic support throughout the study, which is set to continue until 2026. The collaboration with a prestigious institution and the focus on precision neuroscience could significantly enhance Firefly's market position and product offerings.

Firefly Neuroscience, Inc. (AIFF) has been added to the Russell Microcap® Index, which is expected to enhance the company's visibility and attract more institutional investors. This inclusion reflects the company's growth and potential in the neuroscience sector, positioning it favorably within the market. Inclusion in the Russell Microcap® Index is likely to significantly enhance investor interest and market positioning.

Firefly Neuroscience, Inc. has made significant advancements in Alzheimer's research by combining EEG/ERP and vMRI to accurately differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia. The study showed that using both methods together improved diagnostic accuracy to approximately 87%. Firefly's recent acquisition of Evoke Neuroscience enhances its capabilities, leveraging a large database of EEG/ERP records. The findings suggest that these diagnostic tools can be used in clinical settings to improve early detection and intervention for cognitive decline, potentially transforming patient outcomes. The combination of advanced diagnostic methods and the recent acquisition positions Firefly for significant advancements in Alzheimer's detection and treatment.

Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., expanding its database, intellectual property portfolio, and commercial footprint significantly. The acquisition includes a proprietary database of over 180,000 EEG/ERP assessment records, 27 granted patents, and more than 60 commercial users. The purchase terms involve $6 million, split between cash and Firefly's common stock, with potential earn-out for Evoke investors based on future revenues. This move is seen as a strategic step towards building a proprietary foundation model of the human brain using Firefly's Brain Network Analytics technology. The acquisition of Evoke Neuroscience is a significant strategic move that enhances Firefly's technological capabilities and market position.

Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., enhancing its proprietary database with over 180,000 EEG/ERP assessment records, increasing its patent portfolio to 27, and expanding its commercial user base to over 60. The acquisition, valued at $6 million, aims to bolster Firefly's efforts in developing a foundation model of the human brain using its FDA-cleared Brain Network Analytics technology. This strategic move is expected to drive significant growth and innovation for Firefly, leveraging synergies between the two companies. The acquisition significantly enhances Firefly's data assets and commercial capabilities, positioning it for major growth in the brain health technology sector.

Hemostemix and Firefly Neuroscience, Inc. have partnered to complete a Phase 1 clinical trial for ACP-01, targeting vascular dementia. The trial aims to evaluate the safety and efficacy of ACP-01 in patients suffering from this condition, marking a significant step in addressing cognitive decline associated with vascular issues. The collaboration highlights the potential of Brain Network Analytics (BNA(TM)) in enhancing clinical outcomes. The completion of the Phase 1 trial could significantly influence Firefly Neuroscience's market position and investor sentiment regarding its treatment for vascular dementia.

Firefly Neuroscience, Inc. (NASDAQ: AIFF) announced the exercise of warrants resulting in total proceeds of $8.8 million, extending its cash runway into mid-2026. The warrants, exercised at prices of $6.83 and $4.00, were issued during private placements in August and December 2024. The funds will support general working capital and the company's initiative to develop a foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology. Executive Chairman Greg Lipschitz expressed gratitude to shareholders for their confidence in the company's technology. The significant cash infusion and strategic initiative to develop groundbreaking brain health technology are likely to impact Firefly's future performance and market position.

Firefly Neuroscience, Inc. (NASDAQ: AIFF) has been accepted into the NVIDIA Connect program, gaining access to advanced software development resources and technical training. This collaboration aims to support Firefly's initiative to create a foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology, which utilizes EEG data. Executive Chairman Greg Lipschitz highlighted the significance of this milestone as Firefly's BNA™ database expands through ongoing clinical studies. The company targets pharmaceutical firms and medical practitioners for its commercial launch of BNA™. The acceptance into the NVIDIA Connect program and the initiative to build a foundation model of the human brain represent significant strategic advancements that could enhance Firefly's market position and product offerings.

Firefly Neuroscience, Inc. congratulates Dr. Christopher Wilson on receiving the Faculty Research Excellence Award from the University of Waterloo for his contributions to superconducting quantum electronics. Dr. Wilson's research has secured $13 million in funding and he has supervised over 40 students and researchers. He is a key member of Firefly's Advisory Development Board and is currently collaborating on a new brain model initiative. Firefly develops AI solutions to improve brain health outcomes and has launched its FDA-cleared Brain Network Analytics technology for diagnosing and monitoring neurological disorders. Dr. Wilson's recognition and ongoing collaboration on a new brain model initiative could significantly enhance Firefly's product offerings and market position.

Firefly Neuroscience, Inc. (AIFF) announced the publication of research demonstrating the effectiveness of advanced EEG analytics in drug development and neuropsychiatric care. These findings highlight the potential of EEG technology to enhance understanding of brain activity and improve treatment outcomes in various neurological conditions. The publications indicate significant advancements in EEG analytics that could enhance drug development and neuropsychiatric care, potentially altering the company's strategic direction and market position.

Firefly Neuroscience, Inc. has identified a breakthrough cognitive brain age biomarker using its FDA-cleared BNA™ platform. This discovery is expected to enhance the understanding of cognitive health and aging, potentially leading to improved diagnostic and therapeutic strategies in neuroscience. The discovery of a new cognitive brain age biomarker could significantly impact product innovation and market positioning for Firefly Neuroscience.

Firefly Neuroscience, Inc. (AIFF) closes on financing of up to $12.4 million. The significant financing amount is likely to impact the company's future strategic moves and market performance.

Greg Lipschitz appointed as Executive Chairman of Firefly Neuroscience, Inc. The appointment of a new Executive Chairman may moderately influence the company's strategic direction and competitive positioning.

Firefly Neuroscience reported a loss of US$0.61 per share in the third quarter of 2024, compared to a loss of US$0.18 per share in the same period in 2023. The significant increase in loss per share indicates a potential impact on Firefly Neuroscience's future performance and market sentiment.

Firefly Neuroscience, Inc. (AIFF) reports third quarter 2024 results and provides stockholder update. The news of the financial results and stockholder update may moderately influence key areas such as financial performance and investor sentiment.

Firefly Neuroscience granted restricted shares to Executive Chairman David Johnson under Nasdaq Listing Rule 5635(c)(4). The inducement grant may influence key areas like financial performance and leadership stability.